RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

Trial Profile

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Embolism; Stroke; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RELY-ABLE
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2013 Long-term pooled efficacy and safety analysis presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 23 Aug 2013 Additional data will be presented at the 2013 European Society of Cardiology (ESC) Congress, according to a Boehringer Ingelheim media release.
    • 14 Jun 2013 Results published in Circulation, according to Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top